DE1620151C - 10 Piperazino dibenzo square brackets on a, square brackets on cycloheptadiene derivatives and their production process - Google Patents

Description

The present invention relates to 10-piperazinodibenzo [a, d] cycloheptadiene derivatives of the general formula I.

(I)

NO

in which R is a hydrogen atom, a methyl, hydroxyethyl, Hydroxyethoxyethyl, propyne or carbethoxymethyl group, an optionally phenyl-substituted one Ethyl or propenyl group or an optionally substituted by a halogen atom, a methyl, Methoxy, nitro or cyano radical means substituted benzyl group, as well as their pharmaceutically usable ones Salts.

The invention also relates to a process for the preparation of the compounds of the general formula I, that consists in the fact that a reactive ester of the general formula II is used in a manner known per se

(H)

in which X is a reactive ester radical, with a piperazine derivative of the formula III

NO

(III)

in which R has the meanings given above, reacted, being in an inert organic Solvent works under reflux or that, if R is not a hydrogen atom, a reactive one Esters of the general formula IV

X-R '

(IV)

in which X has the meaning given above and R 'has the same meaning as R with the exception of hydrogen possesses, with 10-piperazino-dibenzo [a, d] cycloheptadiene of the formula V

(V)

NH

reacted in an inert organic solvent under reflux.

It is advantageous to use an excess of basic derivatives of the general formulas III or V to work.

The compounds of general formula II can, starting from the corresponding alcohol of Formula VI

(VI)

described by V i 11 a η i et al, J. Med. Pharm. Chem., 5, 373 (1962), according to the usual methods for the preparation of reactive esters, starting from the corresponding alcohols.

Suitable reactive ester radicals are, for. B. a halogen atom, the remainder of a sulfuric acid ester or the methanesulfonyloxy or p-toluenesulfonyloxy radical.

The new compounds of the general formula I can, if appropriate, by physical methods such as distillation, crystallization, chromatography or by chemical methods such as formation of Salts, crystallization of the same and subsequent decomposition can be purified in an alkaline medium. In these operations, the type of anion of the salt does not matter, the only condition is that that the salt is well defined and easily crystallizable.

The new compounds according to the invention and their salts have valuable pharmacodynamic properties Properties on; in particular, they are very effective on the central nervous system as sedatives and antidepressants; they also possess good antihistamine properties and spasmolytic effect and antiserotonin effect. *

It should be noted that the compounds of the general formula VII

40

(VII)

N-Q

in which Q is a hydrogen atom, a methyl or ethyl radical, a hydroxyethyl radical, a hydroxyethoxyethyl radical, a benzyl radical, one substituted in the ring in the o-, m- or p-position by a methyl radical Benzyl radical, a 2-phenylethyl or the cinnamyl radical, are particularly valuable.

For medical use, the new compounds are used either in the form of bases or in the form of pharmaceutically usable,

d. H. in the use doses non-toxic salts.

Examples of pharmaceutically acceptable salts include the salts of mineral acids, for example the hydrochlorides, sulfates, nitrates, phosphates, or of organic acids such as the acetates, propionates, Succinates, benzoates, fumarates, maleates, theophylline acetates, salicylates, phenolphthalinates, methylenebis-ß-oxynaphthoates or of substitution derivatives of these acids.

The salts can be obtained by reacting the bases with acids in suitable solvents. The organic solvents used are, for example, alcohols, ethers, ketones or chlorinated ones Solvent. The salt formed precipitates, if necessary after concentrating its solution, and is through Separated by filtration or decanting.

The medicinal preparations contain one or more of the compounds according to the invention in Form of the bases or the salts in pure form or together with a diluent or coating agent and / or various excipients. Particularly suitable are those preparations that suitable for oral, rectal or parenteral administration.

The solid preparations for oral administration can be in the form of tablets, pills, powders or Granules are present. In these preparations the active substance is mixed with one or more inert diluents, such as sucrose, lactose or starch. These preparations can also contain other substances as the diluent, for example a lubricant such as magnesium stearate.

The liquid preparations for oral administration can be in the form of emulsions, solutions, suspensions, There are syrups and elixirs that contain inert diluents such as water or paraffin oil. These agents can also contain substances other than the diluents, e.g. B. wetting agents, sweeteners or flavoring or odorants.

The preparations for parenteral administration containing the compounds obtainable according to the invention can be sterile aqueous or non-aqueous solutions, suspensions or emulsions. When Solvents or carriers can be propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, and use injectable organic esters such as ethyl oleate. These preparations can also contain adjuvants, in particular wetting agents, emulsifying agents and dispersants. The sterilization can be done in several ways, for example with the help of a bacteriological filter, by incorporating sterilants into the composition, by irradiation or by heating. These preparations can also be made in the form of sterile solid compositions, those at the time of use in sterile water or any other injectable sterile medium can be dissolved.

The preparations for rectal administration are suppositories which, in addition to the active substance, excipients, such as cocoa butter or suppo wax.

The doses to be used depend on the desired therapeutic effect, the route of administration and the duration of treatment: For oral administration they can contain 5 to 100 mg of active substance per day for an adult.

The following examples illustrate the invention.

Ö e i s ρ i e 1 1

To a solution, cooled in an ice bath, of 6.30 g of 10-hydroxydibenzo [a, d] cycloheptadiene in A solution of 10.7 g of thionyl chloride is added within 15 minutes to 60 ecm of anhydrous chloroform in 45 ecm anhydrous chloroform without exceeding 5 ° C. The reaction mixture will Maintained at 5 ° C for 1 hour and then at 25 ° C for 3 hours. The solvents are then im Vacuum evaporated (internal temperature below 30 ° C). The residue obtained is anhydrous in 30 ecm Benzene was added and the solvent was again evaporated in vacuo.

The 10-chlorodibenzo [a, d] cycloheptadiene thus prepared is dissolved in 60 ecm of anhydrous benzene. This solution is added under reflux to a solution of 18.0 g of 1-methylpiperazine in 60 ecm of anhydrous benzene over a period of 10 minutes. The reaction mixture is then refluxed for 18 hours. After cooling, 100 ecm diethyl ether and 100 ecm distilled water are added one after the other. The decanted organic phase is washed three times to neutrality with a total of 150 ecm of distilled water and then extracted successively with 50 ecm of an aqueous 2N acetic acid solution and 15 ecm of an aqueous 2N hydrochloric acid solution. The combined acidic extracts are made alkaline with 15 ecm sodium hydroxide solution (d = 1.33). The product that separates out is extracted three times with a total of 200 ecm of diethyl ether. The combined ether extracts are dried over anhydrous potassium carbonate and then evaporated. The solid residue (4 g) is recrystallized from 30 ecm isopropyl ether. After cooling to 0 ⁰ C, the crystals obtained are drained, washed with 4 cc of ice-cooled isopropyl ether and dried in vacuo. 3.30 g of 10- (4-methylpiperazino) -dibenzo [a, d] cycloheptadiene, melting at 127.5 ° C., are obtained. After recrystallization from ethyl acetate, the pure product melts at 128 ° C.

Example 2

A solution of crude 10-chlorodibenzo [a, d] cycloheptadiene (made from 6.3 g of 10-hydroxydibenzo [a, d] cycloheptadiene) in 60 ecm of anhydrous Benzene is converted into a refluxed solution of 20 g of 1-ethylpiperazine within 25 minutes added in 60 ecm anhydrous benzene. The reaction mixture is then under 20 hours Heated to reflux. After cooling, 100 ecm diethyl ether and 100 ecm distilled water are added. The decanted organic phase is distilled eight times (to neutrality) with a total of 400 ecm Washed water and then successively with 120 ecm of an aqueous 2N acetic acid solution and extracted with 25 ecm aqueous 2η hydrochloric acid. The United Acid extracts are washed with 50 ecm diethyl ether and then with 60 ecm 10 N sodium hydroxide solution made alkaline. The product which separates out is treated twice with a total of 150 ecm of diethyl ether extracted. The combined ethereal solutions are dried over anhydrous potassium carbonate and evaporated. The oily residue (3.7 g) is dissolved in 10 ecm of ethanol and 8 ecm of a solution of dry hydrogen chloride in anhydrous ether (containing 3 moles of hydrogen chloride each Liters). After cooling to 0 ° C, the deposited crystals are suctioned off and three times with a total of 30 ecm of a mixture of equal parts by volume of ether and ethanol. After drying 4.7 g of product are obtained under reduced pressure and are recrystallized from 200 ecm of ethanol. This gives 4.3 g of 10- (4-ethylpiperazino) -dibenzo [a, d] cycloheptadiene dihydrochloride, that melts at around 234 to 235 ° C.

Example 3

A solution of crude 10-chlorodibenzo [a, d] cycloheptadiene (obtained from 6.3 g of 10-hydroxydibenzo [a, d] cycloheptadiene) in 50 ecm anhydrous Benzene is added within 2 hours to a refluxed solution of 25.2 g of 1- (hydroxyethyl) piperazine added in 60 ecm anhydrous benzene. The reaction mixture is then heated

mixture under reflux for 5 hours. After cooling, 100 ecm of diethyl ether and 100 ecm of water are added. The decanted organic phase is washed six times (until neutral) with a total of 600 ecm of distilled water and then extracted three times with 120 ecm of an aqueous 1N methanesulfonic acid solution. The combined acidic extracts are washed with 50 ecm diethyl ether and then made alkaline with 20 ecm 10 η sodium hydroxide solution. The base is extracted twice with a total of 100 ecm of methylene chloride, and the solution obtained is dried over anhydrous sodium sulfate and evaporated. The solid residue (4 g) is recrystallized from 30 ecm isopropyl ether. After cooling to 0 ⁰ C, the crystals obtained are filtered off with suction and washed with 5 cc of isopropyl ether. F. dibenzo [a, d] cycloheptadiene, 100 ⁰ C. - After drying under reduced pressure gives 3.8 g of 10- (4-hydroxyethyl - piperazino)

Example 4

20th

The procedure is as in Example 3, except that 6.3 g of 10-hydroxydibenzo [a, d] and cycloheptadiene are used 31.3g of 1-Hydroxyäthoxyäthyl-piperazin and receives after recrystallization from 45 ecm isopropyl ether 4.6 g of 10- (4-Hydroxyäthoxyäthylpiperazino) -dibenzo [a, d] cycloheptadiene, mp 72 ° C.

Example 5

Man. works as in Example 3, but starts from 15.8 g of 10-hydroxydibenzo [a, d] and cycloheptadiene 43 g of anhydrous piperazine and thus obtained after recrystallization from 25 ecm of isopropyl ether 5.6 g 10-piperazinodibenzo [a, d] cycloheptadiene, mp 114 ° C.

Example 6

The procedure is as in Example 3, except that 6.3 g of 10-hydroxydibenzo [a, d] and cycloheptadiene are used 20.6 g of 1-cinnamylpiperazine, heated under reflux for 20 hours and obtained after recrystallization from 30 ecm of isopropyl ether 5.2 g of 10- (4-cinnamylpiperazino) -dibenzo [a, d] cycloheptadiene, M.p. 95 ° C.

B e i s ρ i e 1 7

The procedure is as in Example 3, except that 6.3 g of 10-hydroxydibenzo [a, d] and cycloheptadiene are used 31.5 g of 1-benzylpiperazine from and heated under reflux for 20 hours and thus obtained after recrystallization from 120 ecm isopropyl ether 4.1g 10- (4-benzylpiperazino) -dibenzo [a, d] cycloheptadiene, 143 ° C.

Example 8

The procedure is as in Example 3, except that 6.3 g of 10-hydroxydibenzo [a, d3cycloheptadiene and 34 g of 1- (3-methylbenzyl) piperazine are used and the mixture is heated under reflux for 20 hours. F. dibenzo [a, d] cycloheptadiene, 110 ⁰ C. - are thus obtained after recrystallization from heptane 4.6 g 60ecm 10- [4- (3-methylbenzyl) - piperazino]

60 B eis ρ ie 1 9

. To a solution of 0.47 g of 10-piperazinodibenzo [a, d] cycloheptadiene in 10 ecm of anhydrous ethanol is a solution of 0.11 g of benzyl chloride in 10 ecm of anhydrous ethanol. The reaction mixture is refluxed for 7 hours. Then the ethanol is evaporated under reduced pressure. The residue is taken up in 6 ecm 2 n-methanesulfonic acid and 20 ecm ether. the acidic solution is decanted off and then gradually added by adding an aqueous sodium bicarbonate solution adjusted to pH 5. The oil that appears is extracted three times with a total of 70 ecm of ether. The combined ether solutions are dried over anhydrous magnesium sulfate and evaporated. The residue (0.31 g) is recrystallized from ethyl acetate. 0.16 g of 10- (4-benzylpiperazino) -dibenzo [a, d] cycloheptadiene are obtained, F. 145 to 146 ° C.

B e i s ρ ie I 10

A solution of 4.70 g of p-methoxybenzyl chloride in 20 ecm of anhydrous ethanol is added to a solution of 16.7 g of 10-piperazine odibenzo- [a, d] cycloheptadiene in 250 cc of anhydrous ethanol. The reaction mixture is refluxed for 11 hours. The ethanol is evaporated under reduced pressure. The residue obtained is treated with 70 ecm 2 n-methanesulfonic acid, 50 ecm distilled water and 120 ecm ether. The acidic solution is decanted off and then gradually adjusted to pH 5 by adding a 2N sodium hydroxide solution. The oil that appears is extracted with 200 ecm of methylene chloride and then washed three times with a total of 300 ecm of distilled water. After drying over anhydrous sodium sulfate, the methylene chloride solution is evaporated. The oily residue (8.9 g) is dissolved in 35 ecm boiling acetonitrile. After cooling to 3 ° C. for 4 hours, the crystals formed are filtered off with suction, washed twice with a total of 20 ecm of ice-cold acetonitrile and dried under vacuum. F. This gives 6.65 g of 10- [4- (4-methoxybenzyl) piperazino] -dibenzo [a, d] cycloheptadiene, 130 ⁰ C.

Example 11

The procedure is as in Example 10, but 16.7 g of 10-piperazinodibenzo [a, d] and cycloheptadiene are used 4.83 g of p-chlorobenzyl chloride and obtained so after Crystallize from 120 ecm ethyl acetate 9.6 g 10 - [4 - (4 - chlorobenzyl) - piperazino] - dibenzo [a, d] cycloheptadiene, mp 164 ° C.

Example 12

You work as in example 10, but start with

15.0 g of 10-piperazinodibenzo [a, d] cycloheptadiene and 3.90 g of p-fluorobenzyl chloride and thus obtained Recrystallization from 25 ecm of isopropyl ether 5.2 g of 10 - [4 - (4 - fluorobenzyl) - piperazino] - dibenzo [a, d] -cycloheptadiene, 98 ° C.

Example 13

You work as in example 10, but start with 36.7 g of 10-piperazinodibenzo [a, d] cycloheptadiene and 11.35 g of p-nitrobenzyl chloride and thus obtained Recrystallization from 300 ecm ethyl acetate

22.1 g of 10- [4- (4-nitrobenzyl) piperazino] dibenzo- [a, d] cycloheptadiene, 172 ° C.

■ B ei s ρ ie I 14

A solution of crude 10-chlorodiberizo [a, d] -cycloheptadiene (obtained from 21.0 g of 10-hydroxydibenzo [a, d] cycloheptadiene) in 150 ecm of anhydrous benzene becomes an under within 30 minutes Refluxing solution of 38.0 g of 1- (I-phenylethyl) piperazine added in 150 ecm anhydrous benzene. The reaction mixture is then

Heated under reflux for 13 hours. After cooling, 150 ecm ether, 200 ecm distilled water and 10 ecm sodium hydroxide solution (d = 1.33) are added. The decanted organic solution is extracted three times with a total of 390 ecm 2 of n-methanesulfonic acid. The combined acidic solutions are washed with 150 ecm diethyl ether and made alkaline with 100 ecm sodium hydroxide solution (d = 1.33). The oil which separates out is extracted twice with a total of 400 ecm of diethyl ether. The combined ether solutions are washed with distilled water until neutral, dried over anhydrous potassium carbonate and evaporated. The residue (14.4 g) consists of a mixture of the two diastereoisomers of 10- [4- (1-phenylethyl) piperazino] dibenzo- [a, d] cycloheptadiene. These two forms can be separated in the following way: The residue (14.4 g) is dissolved in 40 ecm of ethyl acetate while warm. After cooling to 3 ° C. for 6 hours, the crystals formed are filtered off with suction, washed twice with a total of 25 ecm of ice-cold ethyl acetate and dried under reduced pressure. 7.9 g of crystals A, which ^{melt at about 105 to 110 °} C., are obtained. A residue A '(fog) is obtained by evaporating the filtrate.

By recrystallizing crystals A (7.9 g) from 30 ecm of ethyl acetate, 4.6 g of crystals B, which melt at about 114 ° to 118 ° C., are isolated. By treatment of these crystals B in 35 cc of acetonitrile with 6.65 g of picric acid is isolated a crystallized Dipikrat C (10.2 g), which melts at about 199-200 ⁰ C. By treating the Dipikrats C with an aqueous ethanol amine solution to obtain 4.0 g of an oily base, from which, after treatment with 55 cc of isopropyl ether 2.17 g of crystals D isolated, melting at about 13O ⁰ C. Recrystallization from isopropyl ether gives crystals E which melt sharply at 136 ° C. and consist of one of the pure forms (called «form) of 10-f_4- (l-phenylethyl) piperazino] -dibenzo [a, d] cyclopentadiene .

The residue A '(6.5 g) is dissolved in 45 ecm of acetonitrile and treated with 9.95 g of picric acid, with a crystallized 'Dipicrate B' (10.4 g) melting at about 185-187 ° C. By treatment this Dipikrats B 'with an aqueous ethanolamine solution can be isolated 4.05 g of an oily base, the after dissolving in 62 ecm isopropyl ether in the heat on cooling to 3 to 5 ° C for 15 hours 3.15 g of Crystals C, m.p. 96 to 98 ° C, provide. The melting point changes due to recrystallization not from isopropyl ether. These crystals C represent the second form (called ß-form) of the 10 - [4 - (1 - phenylethyl) - piperazino] - dibenzo [a, d] cycloheptadiene. ■ '■.; ■

The 1- (1-phenylethyl) piperazine used as the starting substance (Bp 0.25 = 114 to 115 ° C) is through Implementation of 1-chloro-1-phenylethane with anhydrous ■ Piperazine made in ethanol. -

. _i ... _. ; vBe'ls'p'ie'I 15 "- ^{; /} '■' ■■ ^: "'■ -

A solution of crude 10-chlorodibenzo [a, d] -eyeloheptadiene (obtained from 6.3 g of 10-hydroxydibenzo [a, d] cycloheptadiene) in 60 ecm of anhydrous benzene becomes a refluxing solution within 30 minutes of 22.8 g of 1- (2-methylbenzyO-piperazine in 60 ecm anhydrous benzene are added. Heating under reflux is continued for 20 hours. After cooling, 100 ecm ether and 100 ecm water are added. The decanted organic layer is washed with 10 Washed water (until neutral), extracted four times with a total of 150 ecm 1 n-methanesulfonic acid and washed with 60 ecm water. The acidic extracts are washed with 60 ecm ether and then made alkaline with 20 ecm sodium hydroxide solution (d = 1.33) . The base

ίο is three times with a total of 150 ecm of methylene chloride extracted. The solution obtained is dried over anhydrous sodium sulfate and concentrated under reduced pressure Pressure a. The 7.3 g of crude base obtained are recrystallized from 45 ecm of heptane. You get so 4.8g 10- [4- (2-methylbenzyl) -piperazino] -dibenzo- [a, d] cycloheptadiene, mp 138 ° C.

The 1- (2-methylbenzyl) piperazine (boiling point _0-9 = 113 to 115 ° C.) is obtained by reacting 2-methylbenzyl bromide with piperazine in methanol.

Example 16

One works as in example 15, but replaces that

1 - (2 - methylbenzyl) piperazine through 1 - (4 - methylbenzyl) piperazine and thus obtained after recrystallization from heptane 3.6 g of 10- [4- (4-methylbenzyl) -piperazino] -dibenzo [a, d] cycloheptadiene, Mp 135 ° C.

Example 17

The procedure is as in Example 15, except that 17.9 g of 10-hydroxydibenzo [a, d] cycloheptadiene are used derived 10-chlorodibenzo [a, d] cycloheptadiene and 31.5 g of 1-allylpiperazine from. One receives so after Recrystallization from isopropanol 11.4 g of 10- (4-AlIyI-piperazino) -dibenzo [a, d] cycloheptadiene, F. 80 to 82 ° C.

B e i s ρ i e 1 18

You work as in example 15, but assume 17.9 g of 10-hydroxydibenzo [a, d] cycloheptadiene derived from 10-chlorodibenzo [a, d] cycloheptadiene and 31 g of l- (propyn-2-yl) piperazine and thus, after recrystallization from isopropanol, 6.2 g of 10- [4- (propyne - 2 - yl) - piperazino] - dibenzo [a, d] cycloheptadiene,

Mp 131 ° C.

Example 19

A solution of 3.7 g of 1-chloromethyl-4-cyanobenzene in 50 ecm of ethanol is added within 10 minutes to a refluxed solution of 13.5 g of 10-piperazinodibenzoCa ^ cycloheptadiene in 200 ecm of ethanol. The mixture is refluxed for 18 hours. It is then allowed to cool and the insoluble material is filtered off and washed with 45 ecm of ethanol. It is recrystallized from 350 ecm ethyl acetate. This gives 8.1 g of 10- [4- (4-cyanobenzyl) - piperazino] - dibenzo [a, d] cycloheptadiene, F. 202 ⁰ C.

B e i s ρ i e 1 20

The procedure is as in Example 15, except that 10-chlorodibenzo [a, d] cycloheptadiene derived from 17.9 g of 10-hydroxydibenzo [a, d] cycloheptadiene and 43 g of l-ethoxycarbonylmethylpiperazine (b.p. ₈ = 110 to 112) are used ° C) and thus after recrystallization from isopropyl ether 11.1 g of 10- (4-Äthqxycarbonylmethyl-piperazinoi-dibenzoquäJcycioheptadiene, mp.79'C.

209 608/158

Example 21

Tablets with the following composition are produced according to the usual procedure:

10- (4-methyl-piperazino) -

dibenzo [a, d] cycloheptadiene 5 mg

Strength 110 mg

Colloidal silica 32 mg

Magnesium stearate 3 mg.

Example 22

Tablets with the following composition are produced according to the usual procedure:

10- (4-methyl-piperazino) -

dibenzo [a, d] cycloheptadiene 25 mg

Strength 92 mg

Colloidal silica 30 mg

Magnesium stearate 3 mg

Example 23

Tablets with the following composition are produced according to the usual procedure:

10- (4-hydroxyethyl piperazino) -

dibenzo [a, d] cycloheptadiene 25 mg

Strength 92 mg

Colloidal silica 30 mg

Magnesium stearate: 3 mg

IO

20th

35

40

45

30th

Comparative experiments

Sedative Activity - Electric Shock Combat Test (Mouse)

The experiment is carried out on male mice weighing 18 to 28 g, which one without isolation beforehand, makes people addicted to quarrels by touching a metal plate on which animals 2 and 2 be set, applies an electric current.

The DA _{50 of} a product is the dose that suppresses the struggle caused by electric shock at the level of its effect in 50% of the mice pairs (the struggle is considered suppressed if no more than three attacks are made during an observation period of 3 minutes).

Antihistamirical Activity

(Method of B ο ν e t — S deaf on guinea pigs)

Mari administered varying doses of the product to be examined by subcutaneous route (sc) or per os to guinea pigs. After 30 minutes (if administered subcutaneously) or 90 minutes (if administered orally), 500 toxic doses of histamine are injected intravenously. The killing corresponding to each dose of the product examined is recorded, then the dose is calculated which protects 50% of the animals against these 500 lethal doses of histamine (DAj ₀ ).

toxicity

The dose (in mg kg po) of the product (DL ₃₀ ) which, when administered orally to mice, causes the killing of 50% of the animals is determined.

Toxicity I. DL ₅₀ in anti-
histaminic Sedatives Examples mg / kg p.o. activity
DA ₅₀ in activity
DA ₅₀ in 175 mg / kg mg / kg P-O- 1 165 0.45 p. O. 2.5 • 2 160 0.35 s. C. 4th 3 .150 0.4 s. C. 6.5 4th 85 0.5 s. C. 6.2 5 above 800 0.6 s. C. 2.5 6th 1320 8th 7 = 9 above 800 1.4 p. O. 8th 650 1.5 p.o. 10 above 1600 2 p. O. 11th 1200 2.5 p. O. 12th 1470 2.2 p. O. 13th above 900 1.8 p. O. 14th above 800 1.6 p. O. 15th above 800 3.4 p. O. 12th 16 160 2.6 p. O. 17th 300 0.3 s. C. 18th above 1600 10 19th 550 5.2 p. O. 20th 0.35 s. C. Amitryp 220 tilin *) .... 18 s. C. > 20 p. O. 25th Example 1 of the Belgian Patent specification 230 616 905 ... > 20 p. O. > 20 s. C.

*) S-iS-DimethylaminopropylidenJ-dibenzo ^ .dJcycloheptadiene.

Claims (4)

Patent claims: 1. 10 - piperazino - dibenzo [a, d] cycloheptadiene derivatives of the general formula I. NO 55 in which R is a hydrogen atom, a methyl, hydroxyethyl, hydroxyethoxyethyl, propyne or Carbethoxymethyl group, an optionally phenyl-substituted ethyl or propenyl group or one optionally substituted by a halogen atom, a methyl, methoxy, nitro or cyano radical Benzyl group and their pharmaceutically acceptable salts. 2. 10 - (4-methylpiperazino) - dibenzo [a, d] cycloheptadiene. 3. 10 - (4 - Benzylpiperazino) - dibenzo [a, d] cycloheptadiene. 4. Process for the preparation of the compounds according to one of claims 1 to 3, characterized in that that one in a known manner a reactive ester of the general formula II (H) in which X is a reactive ester radical, with a piperazine derivative of the general formula III HN NO (III) in which R has the meanings given in claim 1, where one is in a inert * organic solvent under reflux works, or that, when R is not a hydrogen atom, a reactive ester of general formula IV X-R ' (IV) in which X has the meanings given above and R 'has the same meaning as R with the exception of hydrogen, with 10-piperazino-dibenzo [a, d] cycloheptadiene of Formula V (V) NH reacted in an inert organic solvent under reflux.